SPR Therapeutics announces 1000th placement of nerve stimulation device

SPR Therapeutics announced the 1000th commercial placement of its Sprint peripheral nerve stimulation (PNS) system for […]

SPR Therapeutics announced the 1000th commercial placement of its Sprint peripheral nerve stimulation (PNS) system for treating pain.
Dr. Henry Vucetic of University Hospitals Case Medical Center (Cleveland) performed the 1000th procedure, treating a patient with shoulder pain due to osteoarthritis.
The Sprint PNS system is the only percutaneous PNS device cleared by the FDA for treating both chronic and acute pain, while also being the only PNS system that doesn’t require permanent implantation, according to a news release.
Physicians place the Spring PNS system leads during an outpatient procedure without surgery, incisions, tissue destruction or anesthesia. They are connected to a wearable stimulator designed to deliver stimulation for up to 60 days of treatment. According to SPR Therapeutics, multiple studies of the system have shown significant and sustained pain relief, with the treated types of pain including post-amputation pain, inoperable joint pain, lower back pain, nerve injury and postoperative pain following joint replacement.
Cleveland-based SPR Therapeutics said the Sprint PNS system is offered at several medical institutions, including Mayo Clinic, the Cleveland Clinic and more across 20 major U.S. cities.
“Hundreds of patients have been treated with Sprint in our published clinical studies, and to now be providing Sprint commercially to our interventional pain physician partners and over a thousand commercial patients is such a fulfilling milestone for SPR,” SPR Therapeutics founder & CEO, Maria Bennett said in the release. “The Sprint system is placed in a minimally invasive procedure well suited to help manage shoulder pain, low back pain, and post-operative pain, for example, without opioids.  Amidst the opioid crisis, Sprint offers a solution for pain for such a time as this, offering hope and health for the millions who suffer chronic and acute pain.”
“Many of our patients do not want to take opioids or have a permanent implant, so Sprint provides a welcome alternative treatment option,” added. Vucetic. “My partner, Dr. Katherine Guran, and I have now treated nearly 50 patients since we started offering Sprint. The first patient Dr. Guran treated, my father, is now well over a year since his treatment ended and he is still virtually pain-free.”
Original Article: (https://www.massdevice.com/spr-therapeutics-announces-1000th-placement-of-nerve-stimulation-device/)